The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Celebrating Valentine's Day: A Sweet Treat for Hepatitis C

Back to News Homepage

Next

Ten Tips to Relieve HCV-Related Itching

First-in-Class HCV Drug Licensed by Novartis

February 16, 2010

Print this page

Novartis licenses alisporivir, a new drug that is currently in Phase IIb development for the treatment of Hepatitis C.

Novartis licenses Hepatitis C drug

Feb. 9, 2010

By Steve Goldstein

LONDON (MarketWatch) — Novartis /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 53.73, +0.02, +0.04%) /quotes/comstock/06p!novn (CH:NOVN 57.80, 0.00, 0.00%) said it has licensed Debio 025, or alisporivir, a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.

Continue reading this entire article:
http://www.marketwatch.com/story/novartis-licenses-hepatitis-c-drug-2010-02-09

No Comments - be the first!
Share
Share

Previous

Celebrating Valentine's Day: A Sweet Treat for Hepatitis C

Back to News Homepage

Next

Ten Tips to Relieve HCV-Related Itching

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.